ACA
ORIAU

Arena Capital Advisors’s Orion Biotech Opportunities Corp. Units ORIAU Stock Holding History

Arena Capital Advisors’s Portfolio ORIAU Stock Details ORIAU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-600,000
Closed -$6.03M – 418
2021
Q2 		$6.03M Buy
+600,000
New +$6.05M 0.5% 61

Other funds holding ORIAU

JP
JNE Partners London, United Kingdom $244M AUM 15.73% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Arena Capital Advisors's ORIAU Position: Q3 2021 in Review

Arena Capital Advisors sold out of Orion Biotech Opportunities Corp. Units (ORIAU) in Q3 2021, closing a stake of 600,000 shares — an estimated $6.03M sold.

Arena Capital Advisors first reported a position in ORIAU in Q2 2021 and held it in 1 quarter. The position peaked at $6.03M in Q2 2021. 21 funds tracked by Wall St. Rank hold ORIAU as of Q3 2021.

  • Arena Capital Advisors reported no remaining Orion Biotech Opportunities Corp. Units position as of Q3 2021 after selling out during the quarter.
  • Arena Capital Advisors sold 600,000 Orion Biotech Opportunities Corp. Units shares in Q3 2021, an estimated $6.03M.
  • Arena Capital Advisors first reported a position in Orion Biotech Opportunities Corp. Units in Q2 2021 and held it in 1 quarter.
  • Arena Capital Advisors's Orion Biotech Opportunities Corp. Units position peaked at $6.03M in Q2 2021.
  • 21 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Units as of Q3 2021.

Based on Arena Capital Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.